INTRODUCTION
• Ankylosing spondylitis (AS) is a progressive, irreversible arthritic disease that causes pain and severe physical impairments that negatively impact health-related quality of life and social functioning.
1,2
• Treatment guidelines for AS recommend treatment with a licensed biologic therapy for patients with an inadequate response to conventional therapy.
3,4
• Until recently, all available biologic therapies were tumour necrosis factor-alpha (TNF-α) inhibitors. However, the recent Assessment of SpondyloArthritis guidelines are the first to also recommend secukinumab, a first-in-class monoclonal antibody that selectively inhibits interleukin-17A. 4 • Secukinumab has recently received final positive recommendations in AS from both the National Institute for Health and Care Excellence (NICE) in England and Wales and the Scottish Medicines Consortium (SMC) in Scotland. These recommendations were reached within just 10 and 8 months of licensing, respectively.
5,6
Budget Impact of Secukinumab for Ankylosing Spondylitis in the UK 
CONCLUSIONS
• Secukinumab represents a treatment for patients with active AS in the UK that is at least as effective as current biologic treatment options and results in cost savings to the NHS due to lower ongoing total drug acquisition costs. Secukinumab therefore offers both clinical and economic value to the UK NHS.
• Within the context of a pressurised NHS budget, cost savings from secukinumab's introduction may enable at least 1000 more UK patients to be treated for this irreversible and debilitating condition under a flat budget. Table 1 . Projected eligible UK patient population from 2016 to 2020
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Figure 3. Tornado chart -sensitivity of budget impact to changes in model inputs
The total modelled population included prevalent and incident cases of active AS. Dosing recommendations for some treatment options differ between the first year and subsequent years due to differences in the initial loading dose and subsequent maintenance dose regimens. There was therefore a need to model whether patients were receiving a biologic for the first time (incurring "first year" costs) or whether it was assumed they had already received biologics for a year (thereby incurring "subsequent year" costs). For the incident population, it was assumed that in each year these patients would be receiving a biologic for the first time and therefore incur "year 1" costs of biologic treatment. For the prevalent population, it was assumed these patients were already receiving biologic therapy and hence incurred the "subsequent year" costs. The exception to this was the prevalent population in 2016 who received secukinumab; these patients were assumed to incur the "year 1" costs, to reflect the novel introduction of this therapy to the market in this year (i.e. prevalent patients in 2016 could not have already been receiving secukinumab).
OBJECTIVE
• Our objective was to estimate the budget impact, over a 5-year period, of introducing secukinumab as a treatment option for adult patients with active AS who have responded inadequately to conventional therapy. The perspective was that of the United Kingdom (UK) National Health Service (NHS) and Personal Social Services.
RESULTS
• The introduction of secukinumab was estimated to result in cumulative budget savings of approximately £5.0 million over a 2-year period, rising to £49.2 million over 5 years ( Figure 2 ).
• The calculated cost savings were primarily driven by the expected market share shift to secukinumab, which has lower annual drug costs in subsequent treatment years than currently available TNF-α inhibitors. OWSA also found that greater secukinumab usage, modelled through an increased market share estimate, further increased the expected cost savings for the NHS of introducing secukinumab (Figure 3 ).
• The budget impact of introducing secukinumab was most sensitive to the drug acquisition cost of secukinumab (Figure 3) . A confidential patient access scheme (PAS) is available to the UK NHS for secukinumab, which would therefore further increase potential savings beyond those provided for this list price analysis.
• Based on average population size (31,999) and annual drug costs (£9,318) in the world with secukinumab, the £49.2 million cost savings estimated over the next 5 years would equate to sufficient funding, in a flat budget scenario, for biologic therapy for at least 1000 additional patients who would not have been able to receive treatment in the world without secukinumab.
METHODS
• A budget impact model was developed to compare the total expected drug acquisition and drug administration costs for both "world with secukinumab" and "world without secukinumab" scenarios.
• Estimations of the total eligible UK patient population were obtained from the Office for National Statistics, published literature and expert clinical opinion (Figure 1) , and projected from 2016 to 2020 (Table 1 ).
• The model calculations also accounted for gender-specific relative risks of mortality due to AS based on patient age and gender distribution in the pooled MEASURE 2 and MEASURE 1 trials (42.37 years, 69.5% male).
12,13
• All TNF-α inhibitors and biosimilar versions currently available in the UK were included. The efficacy of secukinumab was assumed to be at least equivalent to all TNF-α inhibitors in the short-term, based on published indirect comparisons, and therefore only drug acquisition and administration costs were considered.
14-16
This may represent a conservative assumption given results from a matching-adjusted indirect comparison (MAIC) that found significantly higher symptomatic improvements with secukinumab compared to adalimumab at week 24, and maintenance of higher improvements up to 1 year. 15, 16 • Market share projections obtained from NHiS and internal Novartis data were used to calculate total drug expenditure for each treatment (Table 2) . Drug acquisition costs were sourced from the British National Formulary or the Monthly Index of Medical Specialities for all therapies, and the licensed posology was used for all treatments (Table 3) . The model assumed no discontinuation of any therapies. Costs of background conventional therapy were not included as these costs were assumed to be the same across all therapies and hence have no incremental budgetary impact.
• Drug administration costs for subcutaneous therapies consisted of a one-off cost for 1 hour of nurse training on self-injection (£43).
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DISCUSSION
• The minimally increased costs to the NHS estimated for 2016 were a result of assuming that all prevalent and incident patients receiving secukinumab did so at its higher year 1 cost in this year; prevalent patients receiving established TNF-α inhibitors were assumed to receive the lower "subsequent year" dosing of these therapies.
• Estimates of population size for this analysis were based on UK national statistics and published literature regarding the prevalence and incidence of the disease. The 60% biologic treatment rate for eligible patients was an assumption based on clinical opinion and would benefit from validation through market research.
• The analysis relied on an assumption of no difference in efficacy between secukinumab and the other biologic therapies. Therefore, should differences in efficacy exist, as suggested by the results of the MAIC with adalimumab, the analysis does not account for the potential additional cost savings available with secukinumab.
15,16
• The analysis considered direct costs only and therefore did not account for any potential additional cost savings that might be achieved from a broader societal perspective. Moreover, a confidential PAS is available for secukinumab to the UK NHS, further increasing potential savings.
Figure 2. Total annual cost savings for the treated population in a world with secukinumab compared to a world without
Positive values indicate increased costs to the NHS of introducing secukinumab. Negative values indicate cost savings to the NHS resulting from the introduction of secukinumab.
• Intravenously administered infliximab products were associated with an infusion cost of £326.46 per dose, sourced from NHS Reference Costs and assumed applicable to all of the UK, consistent with acceptance of this input by the SMC in the recent appraisal of secukinumab.
6,18
• One-way sensitivity analyses (OWSA) were performed to assess the impact of changes (±50%) to the acquisition cost and the market share estimates of secukinumab.
Figure 1. Eligible UK patient population flowchart
*Eligibility for treatment with biologic therapy was defined as having active AS that was not responsive to conventional treatment.
Total UK population ≥18 years of age 7 Active AS population (prevalence and incidence) Table 2 . Market share estimates for a world without secukinumab and a world with secukinumab Table 3 . Drug acquisition and administration costs used within the model All therapies were considered at list price. For certolizumab pegol, the patient access scheme (PAS) agreed with NICE that provides the first 12 weeks (10 vials) of certolizumab pegol free of charge was taken into account and assumed to apply to the whole of the UK (the specific details of the PAS agreed with the SMC are not available). The average number of vials required by each patient for infliximab was calculated based on a mean weight of 78.20 kg (SD 16.88 kg) -the mean weight of all patients pooled across the MEASURE 2 and MEASURE 1 trials -and it was assumed that weight was normally distributed. 
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